NCT03616587Active, not recruitingPhase 1
Phase 1 Study of AZD9833 Alone or in Combination in Women with Advanced Breast Cancer
Source: EU CTIS (euclinicaltrials.eu) · Last updated 22 Jul 2026
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 173 (estimated)
- First submitted
- 24 Apr 2024
- Start date
- 1 Mar 2019
- Lead sponsor
- Astrazeneca AB
- Diseases
- Metastatic breast cancer
- NCT number
- NCT03616587
- EU CT number
- 2023-506890-37-00
- EudraCT number
- 2018-000667-92
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 173
- 5 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (5)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Universitari Vall d'Hebron Coordinator of this site? Confirm its status | Barcelona | Spain | Active, not recruiting |
| Hospital Clinic de Barcelona Coordinator of this site? Confirm its status | Barcelona | Spain | Active, not recruiting |
| Hospital Universitario HM Sanchinarro Coordinator of this site? Confirm its status | Madrid | Spain | Active, not recruiting |
| University Hospital Virgen Del Rocio S.L. Coordinator of this site? Confirm its status | Sevilla | Spain | Active, not recruiting |
| Hospital Clinico Universitario de Valencia Coordinator of this site? Confirm its status | Valencia | Spain | Active, not recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.